Search

Your search keyword '"Amatu, Alessio"' showing total 293 results
Start Over Author "Amatu, Alessio"
293 results on '"Amatu, Alessio"'

1. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Author

Desai, Jayesh, Alonso, Guzman, Kim, Se Hyun, Cervantes, Andres, Karasic, Thomas, Medina, Laura, Shacham-Shmueli, Einat, Cosman, Rasha, Falcon, Alejandro, Gort, Eelke, Guren, Tormod, Massarelli, Erminia, Miller, Jr., Wilson H., Paz-Ares, Luis, Prenen, Hans, Amatu, Alessio, Cremolini, Chiara, Kim, Tae Won, Moreno, Victor, Ou, Sai-Hong I., Passardi, Alessandro, Sacher, Adrian, Santoro, Armando, Stec, Rafal, Ulahannan, Susanna, Arbour, Kathryn, Lorusso, Patricia, Luo, Jia, Patel, Manish R., Choi, Yoonha, Shi, Zhen, Mandlekar, Sandhya, Lin, Mark T., Royer-Joo, Stephanie, Chang, Julie, Jun, Tomi, Dharia, Neekesh V., Schutzman, Jennifer L., and Han, Sae-Won

Published
2024
Full Text
View/download PDF

3. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

Author

Sartore-Bianchi, Andrea, Pietrantonio, Filippo, Lonardi, Sara, Mussolin, Benedetta, Rua, Francesco, Crisafulli, Giovanni, Bartolini, Alice, Fenocchio, Elisabetta, Amatu, Alessio, Manca, Paolo, Bergamo, Francesca, Tosi, Federica, Mauri, Gianluca, Ambrosini, Margherita, Daniel, Francesca, Torri, Valter, Vanzulli, Angelo, Regge, Daniele, Cappello, Giovanni, Marchiò, Caterina, Berrino, Enrico, Sapino, Anna, Marsoni, Silvia, Siena, Salvatore, and Bardelli, Alberto

Published
2022
Full Text
View/download PDF

4. Clinicopathological characterisation ofMTAPalterations in gastrointestinal cancers

Author

Mauri, Gianluca, primary, Patelli, Giorgio, additional, Roazzi, Laura, additional, Valtorta, Emanuele, additional, Amatu, Alessio, additional, Marrapese, Giovanna, additional, Bonazzina, Erica, additional, Tosi, Federica, additional, Bencardino, Katia, additional, Ciarlo, Gabriele, additional, Mariella, Elisa, additional, Marsoni, Silvia, additional, Bardelli, Alberto, additional, Bonoldi, Emanuela, additional, Sartore-Bianchi, Andrea, additional, and Siena, Salvatore, additional

Published
2024
Full Text
View/download PDF

5. Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study

Author

Raimondi, Alessandra, Corallo, Salvatore, Lonardi, Sara, Antoniotti, Carlotta, Rimassa, Lorenza, Amatu, Alessio, Tampellini, Marco, Racca, Patrizia, Murialdo, Roberto, Clavarezza, Matteo, Zaniboni, Alberto, Toscano, Giuseppe, Tomasello, Gianluca, Petrelli, Fausto, Antonuzzo, Lorenzo, Giordano, Monica, Cinieri, Saverio, Longarini, Raffaella, Niger, Monica, Antista, Maria, Ambrosini, Margherita, Pagani, Filippo, Prisciandaro, Michele, Randon, Giovanni, de Braud, Filippo, Di Bartolomeo, Maria, Pietrantonio, Filippo, and Morano, Federica

Published
2021
Full Text
View/download PDF

6. Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression

Author

Bonnal, Raoul J. P., Rossetti, Grazisa, Lugli, Enrico, De Simone, Marco, Gruarin, Paola, Brummelman, Jolanda, Drufuca, Lorenzo, Passaro, Marco, Bason, Ramona, Gervasoni, Federica, Della Chiara, Giulia, D’Oria, Claudia, Martinovic, Martina, Curti, Serena, Ranzani, Valeria, Cordiglieri, Chiara, Alvisi, Giorgia, Mazza, Emilia Maria Cristina, Oliveto, Stefania, Silvestri, Ylenia, Carelli, Elena, Mazzara, Saveria, Bosotti, Roberto, Sarnicola, Maria Lucia, Godano, Chiara, Bevilacqua, Valeria, Lorenzo, Mariangela, Siena, Salvatore, Bonoldi, Emanuela, Sartore-Bianchi, Andrea, Amatu, Alessio, Veronesi, Giulia, Novellis, Pierluigi, Alloisio, Marco, Giani, Alessandro, Zucchini, Nicola, Opocher, Enrico, Ceretti, Andrea Pisani, Mariani, Nicolò, Biffo, Stefano, Prati, Daniele, Bardelli, Alberto, Geginat, Jens, Lanzavecchia, Antonio, Abrignani, Sergio, and Pagani, Massimiliano

Published
2021
Full Text
View/download PDF

8. Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer

Author

Tosi, Federica, Sartore-Bianchi, Andrea, Lonardi, Sara, Amatu, Alessio, Leone, Francesco, Ghezzi, Silvia, Martino, Cosimo, Bencardino, Katia, Bonazzina, Erica, Bergamo, Francesca, Fenocchio, Elisabetta, Martinelli, Erika, Troiani, Teresa, Siravegna, Giulia, Mauri, Gianluca, Torri, Valter, Marrapese, Giovanna, Valtorta, Emanuele, Cassingena, Andrea, Cappello, Giovanni, Bonoldi, Emanuela, Vanzulli, Angelo, Regge, Daniele, Ciardiello, Fortunato, Zagonel, Vittorina, Bardelli, Alberto, Trusolino, Livio, Marsoni, Silvia, and Siena, Salvatore

Published
2020
Full Text
View/download PDF

9. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial

Author

Sartore-Bianchi, Andrea, Lonardi, Sara, Martino, Cosimo, Fenocchio, Elisabetta, Tosi, Federica, Ghezzi, Silvia, Leone, Francesco, Bergamo, Francesca, Zagonel, Vittorina, Ciardiello, Fortunato, Ardizzoni, Andrea, Amatu, Alessio, Bencardino, Katia, Valtorta, Emanuele, Grassi, Elena, Torri, Valter, Bonoldi, Emanuela, Sapino, Anna, Vanzulli, Angelo, Regge, Daniele, Cappello, Giovanni, Bardelli, Alberto, Trusolino, Livio, Marsoni, Silvia, and Siena, Salvatore

Published
2020
Full Text
View/download PDF

11. Total neoadjuvant treatment without surgery for locally advanced rectal cancer: Prospective study to assess tumor response, circulating genetic, and epigenetic biomarkers, and stromal transcriptome to interpret clinical outcome (NO-CUT trial).

Author

Siena, Salvatore, primary, Amatu, Alessio, additional, Bencardino, Katia, additional, Zampino, M. Giulia, additional, Bergamo, Francesca, additional, Mosconi, Stefania, additional, Bracco, Francesco, additional, Gerardi, Marianna Alessandra, additional, Galuppo, Sara, additional, Carnevali, Pietro, additional, Petz, Wanda, additional, Pilati, Pierluigi, additional, Tosi, Federica, additional, Mariano, Sara, additional, Bonazzina, Erica, additional, Forti, Edoardo, additional, Ghezzi, Silvia, additional, Pucciarelli, Salvatore, additional, Torri, Valter, additional, and Sartore-Bianchi, Andrea, additional

Published
2023
Full Text
View/download PDF

12. Data from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients

Author

Crisafulli, Giovanni, primary, Sartore-Bianchi, Andrea, primary, Lazzari, Luca, primary, Pietrantonio, Filippo, primary, Amatu, Alessio, primary, Macagno, Marco, primary, Barault, Ludovic, primary, Cassingena, Andrea, primary, Bartolini, Alice, primary, Luraghi, Paolo, primary, Mauri, Gianluca, primary, Battuello, Paolo, primary, Personeni, Nicola, primary, Zampino, Maria Giulia, primary, Pessei, Valeria, primary, Vitiello, Pietro Paolo, primary, Tosi, Federica, primary, Idotta, Laura, primary, Morano, Federica, primary, Valtorta, Emanuele, primary, Bonoldi, Emanuela, primary, Germano, Giovanni, primary, Di Nicolantonio, Federica, primary, Marsoni, Silvia, primary, Siena, Salvatore, primary, and Bardelli, Alberto, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Data from Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies

Author

Janku, Filip, primary, Han, Sae-Won, primary, Doi, Toshihiko, primary, Amatu, Alessio, primary, Ajani, Jaffer A., primary, Kuboki, Yasutoshi, primary, Cortez, Alex, primary, Cellitti, Susan E., primary, Mahling, Ping C., primary, Subramanian, Kulandayan, primary, Schoenfeld, Heidi A., primary, Choi, Sarah M., primary, Iaconis, Lori A., primary, Lee, Lang Ho, primary, Pelletier, Marc R., primary, Dranoff, Glenn, primary, Askoxylakis, Vasileios, primary, and Siena, Salvatore, primary

Published
2023
Full Text
View/download PDF

14. Data from Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies

Author

Janku, Filip, primary, Han, Sae-Won, primary, Doi, Toshihiko, primary, Amatu, Alessio, primary, Ajani, Jaffer A., primary, Kuboki, Yasutoshi, primary, Cortez, Alex, primary, Cellitti, Susan E., primary, Mahling, Ping C., primary, Subramanian, Kulandayan, primary, Schoenfeld, Heidi A., primary, Choi, Sarah M., primary, Iaconis, Lori A., primary, Lee, Lang Ho, primary, Pelletier, Marc R., primary, Dranoff, Glenn, primary, Askoxylakis, Vasileios, primary, and Siena, Salvatore, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure from Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies

Author

Janku, Filip, primary, Han, Sae-Won, primary, Doi, Toshihiko, primary, Amatu, Alessio, primary, Ajani, Jaffer A., primary, Kuboki, Yasutoshi, primary, Cortez, Alex, primary, Cellitti, Susan E., primary, Mahling, Ping C., primary, Subramanian, Kulandayan, primary, Schoenfeld, Heidi A., primary, Choi, Sarah M., primary, Iaconis, Lori A., primary, Lee, Lang Ho, primary, Pelletier, Marc R., primary, Dranoff, Glenn, primary, Askoxylakis, Vasileios, primary, and Siena, Salvatore, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients

Author

Crisafulli, Giovanni, primary, Sartore-Bianchi, Andrea, primary, Lazzari, Luca, primary, Pietrantonio, Filippo, primary, Amatu, Alessio, primary, Macagno, Marco, primary, Barault, Ludovic, primary, Cassingena, Andrea, primary, Bartolini, Alice, primary, Luraghi, Paolo, primary, Mauri, Gianluca, primary, Battuello, Paolo, primary, Personeni, Nicola, primary, Zampino, Maria Giulia, primary, Pessei, Valeria, primary, Vitiello, Pietro Paolo, primary, Tosi, Federica, primary, Idotta, Laura, primary, Morano, Federica, primary, Valtorta, Emanuele, primary, Bonoldi, Emanuela, primary, Germano, Giovanni, primary, Di Nicolantonio, Federica, primary, Marsoni, Silvia, primary, Siena, Salvatore, primary, and Bardelli, Alberto, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure S2 from Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

Author

Bardelli, Alberto, primary, Corso, Simona, primary, Bertotti, Andrea, primary, Hobor, Sebastijan, primary, Valtorta, Emanuele, primary, Siravegna, Giulia, primary, Sartore-Bianchi, Andrea, primary, Scala, Elisa, primary, Cassingena, Andrea, primary, Zecchin, Davide, primary, Apicella, Maria, primary, Migliardi, Giorgia, primary, Galimi, Francesco, primary, Lauricella, Calogero, primary, Zanon, Carlo, primary, Perera, Timothy, primary, Veronese, Silvio, primary, Corti, Giorgio, primary, Amatu, Alessio, primary, Gambacorta, Marcello, primary, Diaz, Luis A., primary, Sausen, Mark, primary, Velculescu, Victor E., primary, Comoglio, Paolo, primary, Trusolino, Livio, primary, Di Nicolantonio, Federica, primary, Giordano, Silvia, primary, and Siena, Salvatore, primary

Published
2023
Full Text
View/download PDF

18. Data from Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Author

Drilon, Alexander, primary, Siena, Salvatore, primary, Ou, Sai-Hong Ignatius, primary, Patel, Manish, primary, Ahn, Myung Ju, primary, Lee, Jeeyun, primary, Bauer, Todd M., primary, Farago, Anna F., primary, Wheler, Jennifer J., primary, Liu, Stephen V., primary, Doebele, Robert, primary, Giannetta, Laura, primary, Cerea, Giulio, primary, Marrapese, Giovanna, primary, Schirru, Michele, primary, Amatu, Alessio, primary, Bencardino, Katia, primary, Palmeri, Laura, primary, Sartore-Bianchi, Andrea, primary, Vanzulli, Angelo, primary, Cresta, Sara, primary, Damian, Silvia, primary, Duca, Matteo, primary, Ardini, Elena, primary, Li, Gang, primary, Christiansen, Jason, primary, Kowalski, Karey, primary, Johnson, Ann D., primary, Patel, Rupal, primary, Luo, David, primary, Chow-Maneval, Edna, primary, Hornby, Zachary, primary, Multani, Pratik S., primary, Shaw, Alice T., primary, and De Braud, Filippo G., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure Legend from Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

Author

Bardelli, Alberto, primary, Corso, Simona, primary, Bertotti, Andrea, primary, Hobor, Sebastijan, primary, Valtorta, Emanuele, primary, Siravegna, Giulia, primary, Sartore-Bianchi, Andrea, primary, Scala, Elisa, primary, Cassingena, Andrea, primary, Zecchin, Davide, primary, Apicella, Maria, primary, Migliardi, Giorgia, primary, Galimi, Francesco, primary, Lauricella, Calogero, primary, Zanon, Carlo, primary, Perera, Timothy, primary, Veronese, Silvio, primary, Corti, Giorgio, primary, Amatu, Alessio, primary, Gambacorta, Marcello, primary, Diaz, Luis A., primary, Sausen, Mark, primary, Velculescu, Victor E., primary, Comoglio, Paolo, primary, Trusolino, Livio, primary, Di Nicolantonio, Federica, primary, Giordano, Silvia, primary, and Siena, Salvatore, primary

Published
2023
Full Text
View/download PDF

20. Data from Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

Author

Bardelli, Alberto, primary, Corso, Simona, primary, Bertotti, Andrea, primary, Hobor, Sebastijan, primary, Valtorta, Emanuele, primary, Siravegna, Giulia, primary, Sartore-Bianchi, Andrea, primary, Scala, Elisa, primary, Cassingena, Andrea, primary, Zecchin, Davide, primary, Apicella, Maria, primary, Migliardi, Giorgia, primary, Galimi, Francesco, primary, Lauricella, Calogero, primary, Zanon, Carlo, primary, Perera, Timothy, primary, Veronese, Silvio, primary, Corti, Giorgio, primary, Amatu, Alessio, primary, Gambacorta, Marcello, primary, Diaz, Luis A., primary, Sausen, Mark, primary, Velculescu, Victor E., primary, Comoglio, Paolo, primary, Trusolino, Livio, primary, Di Nicolantonio, Federica, primary, Giordano, Silvia, primary, and Siena, Salvatore, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure Legends from Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Author

Drilon, Alexander, primary, Siena, Salvatore, primary, Ou, Sai-Hong Ignatius, primary, Patel, Manish, primary, Ahn, Myung Ju, primary, Lee, Jeeyun, primary, Bauer, Todd M., primary, Farago, Anna F., primary, Wheler, Jennifer J., primary, Liu, Stephen V., primary, Doebele, Robert, primary, Giannetta, Laura, primary, Cerea, Giulio, primary, Marrapese, Giovanna, primary, Schirru, Michele, primary, Amatu, Alessio, primary, Bencardino, Katia, primary, Palmeri, Laura, primary, Sartore-Bianchi, Andrea, primary, Vanzulli, Angelo, primary, Cresta, Sara, primary, Damian, Silvia, primary, Duca, Matteo, primary, Ardini, Elena, primary, Li, Gang, primary, Christiansen, Jason, primary, Kowalski, Karey, primary, Johnson, Ann D., primary, Patel, Rupal, primary, Luo, David, primary, Chow-Maneval, Edna, primary, Hornby, Zachary, primary, Multani, Pratik S., primary, Shaw, Alice T., primary, and De Braud, Filippo G., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figures 1 - 2 from Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Author

Drilon, Alexander, primary, Siena, Salvatore, primary, Ou, Sai-Hong Ignatius, primary, Patel, Manish, primary, Ahn, Myung Ju, primary, Lee, Jeeyun, primary, Bauer, Todd M., primary, Farago, Anna F., primary, Wheler, Jennifer J., primary, Liu, Stephen V., primary, Doebele, Robert, primary, Giannetta, Laura, primary, Cerea, Giulio, primary, Marrapese, Giovanna, primary, Schirru, Michele, primary, Amatu, Alessio, primary, Bencardino, Katia, primary, Palmeri, Laura, primary, Sartore-Bianchi, Andrea, primary, Vanzulli, Angelo, primary, Cresta, Sara, primary, Damian, Silvia, primary, Duca, Matteo, primary, Ardini, Elena, primary, Li, Gang, primary, Christiansen, Jason, primary, Kowalski, Karey, primary, Johnson, Ann D., primary, Patel, Rupal, primary, Luo, David, primary, Chow-Maneval, Edna, primary, Hornby, Zachary, primary, Multani, Pratik S., primary, Shaw, Alice T., primary, and De Braud, Filippo G., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Tables 1-6 from Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Author

Drilon, Alexander, primary, Siena, Salvatore, primary, Ou, Sai-Hong Ignatius, primary, Patel, Manish, primary, Ahn, Myung Ju, primary, Lee, Jeeyun, primary, Bauer, Todd M., primary, Farago, Anna F., primary, Wheler, Jennifer J., primary, Liu, Stephen V., primary, Doebele, Robert, primary, Giannetta, Laura, primary, Cerea, Giulio, primary, Marrapese, Giovanna, primary, Schirru, Michele, primary, Amatu, Alessio, primary, Bencardino, Katia, primary, Palmeri, Laura, primary, Sartore-Bianchi, Andrea, primary, Vanzulli, Angelo, primary, Cresta, Sara, primary, Damian, Silvia, primary, Duca, Matteo, primary, Ardini, Elena, primary, Li, Gang, primary, Christiansen, Jason, primary, Kowalski, Karey, primary, Johnson, Ann D., primary, Patel, Rupal, primary, Luo, David, primary, Chow-Maneval, Edna, primary, Hornby, Zachary, primary, Multani, Pratik S., primary, Shaw, Alice T., primary, and De Braud, Filippo G., primary

Published
2023
Full Text
View/download PDF

24. Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients

Author

Sartore-Bianchi, Andrea, Pietrantonio, Filippo, Amatu, Alessio, Milione, Massimo, Cassingena, Andrea, Ghezzi, Silvia, Caporale, Marta, Berenato, Rosa, Falcomatà, Chiara, Pellegrinelli, Alessio, Bardelli, Alberto, Nichelatti, Michele, Tosi, Federica, De Braud, Filippo, Di Nicolantonio, Federica, Barault, Ludovic, and Siena, Salvatore

Published
2017
Full Text
View/download PDF

25. Supplementary Table S1 from A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin

Author

Arena, Sabrina, primary, Corti, Giorgio, primary, Durinikova, Erika, primary, Montone, Monica, primary, Reilly, Nicole M., primary, Russo, Mariangela, primary, Lorenzato, Annalisa, primary, Arcella, Pamela, primary, Lazzari, Luca, primary, Rospo, Giuseppe, primary, Pagani, Massimiliano, primary, Cancelliere, Carlotta, primary, Negrino, Carola, primary, Isella, Claudio, primary, Bartolini, Alice, primary, Cassingena, Andrea, primary, Amatu, Alessio, primary, Mauri, Gianluca, primary, Sartore-Bianchi, Andrea, primary, Mittica, Gloria, primary, Medico, Enzo, primary, Marsoni, Silvia, primary, Linnebacher, Michael, primary, Abrignani, Sergio, primary, Siena, Salvatore, primary, Di Nicolantonio, Federica, primary, and Bardelli, Alberto, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Legends and Figures from A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin

Author

Arena, Sabrina, primary, Corti, Giorgio, primary, Durinikova, Erika, primary, Montone, Monica, primary, Reilly, Nicole M., primary, Russo, Mariangela, primary, Lorenzato, Annalisa, primary, Arcella, Pamela, primary, Lazzari, Luca, primary, Rospo, Giuseppe, primary, Pagani, Massimiliano, primary, Cancelliere, Carlotta, primary, Negrino, Carola, primary, Isella, Claudio, primary, Bartolini, Alice, primary, Cassingena, Andrea, primary, Amatu, Alessio, primary, Mauri, Gianluca, primary, Sartore-Bianchi, Andrea, primary, Mittica, Gloria, primary, Medico, Enzo, primary, Marsoni, Silvia, primary, Linnebacher, Michael, primary, Abrignani, Sergio, primary, Siena, Salvatore, primary, Di Nicolantonio, Federica, primary, and Bardelli, Alberto, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table 1 from Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer

Author

Amatu, Alessio, primary, Sartore-Bianchi, Andrea, primary, Moutinho, Catia, primary, Belotti, Alessandro, primary, Bencardino, Katia, primary, Chirico, Giuseppe, primary, Cassingena, Andrea, primary, Rusconi, Francesca, primary, Esposito, Anna, primary, Nichelatti, Michele, primary, Esteller, Manel, primary, and Siena, Salvatore, primary

Published
2023
Full Text
View/download PDF

28. Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

Author

Mauri, Gianluca, primary, Patelli, Giorgio, additional, Gori, Viviana, additional, Lauricella, Calogero, additional, Mussolin, Benedetta, additional, Amatu, Alessio, additional, Bencardino, Katia, additional, Tosi, Federica, additional, Bonazzina, Erica, additional, Bonoldi, Emanuela, additional, Bardelli, Alberto, additional, Siena, Salvatore, additional, and Sartore-Bianchi, Andrea, additional

Published
2023
Full Text
View/download PDF

30. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Author

Sartore-Bianchi, Andrea, Trusolino, Livio, Martino, Cosimo, Bencardino, Katia, Lonardi, Sara, Bergamo, Francesca, Zagonel, Vittorina, Leone, Francesco, Depetris, Ilaria, Martinelli, Erika, Troiani, Teresa, Ciardiello, Fortunato, Racca, Patrizia, Bertotti, Andrea, Siravegna, Giulia, Torri, Valter, Amatu, Alessio, Ghezzi, Silvia, Marrapese, Giovanna, Palmeri, Laura, Valtorta, Emanuele, Cassingena, Andrea, Lauricella, Calogero, Vanzulli, Angelo, Regge, Daniele, Veronese, Silvio, Comoglio, Paolo M, Bardelli, Alberto, Marsoni, Silvia, and Siena, Salvatore

Published
2016
Full Text
View/download PDF

31. Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)

Author

Ricotta, Riccardo, Verrioli, Antonella, Ghezzi, Silvia, Porcu, Luca, Grothey, A., Falcone, Alfredo, Van Cutsem, Eric, Argilés, Guillem, Adenis, Antoine, Ychou, Marc, Barone, Carlo, Bouché, Olivier, Peeters, Marc, Humblet, Yves, Mineur, Laurent, Sobrero, Alberto F., Hubbard, Joleen M., Cremolini, Chiara, Prenen, Hans, Tabernero, Josep, Jarraya, Hajer, Mazard, Thibault, Deguelte-Lardiere, Sophie, Papadimitriou, Konstantinos, Van den Eynde, Marc, Pastorino, Alessandro, Redaelli, Daniela, Bencardino, Katia, Funaioli, Chiara, Amatu, Alessio, Carlo-Stella, Giulia, Torri, Valter, Sartore-Bianchi, Andrea, Vanzulli, Angelo, and Siena, Salvatore

Published
2016
Full Text
View/download PDF

34. Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

Author

Mauri, Gianluca, primary, Patelli, Giorgio, additional, Gori, Viviana, additional, Lauricella, Calogero, additional, Mussolin, Benedetta, additional, Amatu, Alessio, additional, Bencardino, Katia, additional, Tosi, Federica, additional, Bonazzina, Erica, additional, Bonoldi, Emanuela, additional, Bardelli, Alberto, additional, Siena, Salvatore, additional, and Sartore-Bianchi, Andrea, additional

Published
2022
Full Text
View/download PDF

35. Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience

Author

Sartore-Bianchi, Andrea, Amatu, Alessio, Bonazzina, Erica, Stabile, Stefano, Giannetta, Laura, Cerea, Giulio, Schiavetto, Ilaria, Bencardino, Katia, Funaioli, Chiara, Ricotta, Riccardo, Cipani, Tiziana, Schirru, Michele, Gambi, Valentina, Palmeri, Laura, Carlo-Stella, Giulia, Rusconi, Francesca, Di Bella, Sara, Burrafato, Giovanni, Cassingena, Andrea, Valtorta, Emanuele, Lauricella, Calogero, Pazzi, Federica, Gambaro, Alessandra, Ghezzi, Silvia, Marrapese, Giovanna, Tarenzi, Emiliana, Veronese, Silvio, Truini, Mauro, Vanzulli, Angelo, and Siena, Salvatore

Published
2017
Full Text
View/download PDF

36. Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies

Author

Janku, Filip, primary, Han, Sae-Won, additional, Doi, Toshihiko, additional, Amatu, Alessio, additional, Ajani, Jaffer A., additional, Kuboki, Yasutoshi, additional, Cortez, Alex, additional, Cellitti, Susan E., additional, Mahling, Ping C., additional, Subramanian, Kulandayan, additional, Schoenfeld, Heidi A., additional, Choi, Sarah M., additional, Iaconis, Lori A., additional, Lee, Lang Ho, additional, Pelletier, Marc R., additional, Dranoff, Glenn, additional, Askoxylakis, Vasileios, additional, and Siena, Salvatore, additional

Published
2022
Full Text
View/download PDF

38. Abstract 6262: Emergence of tumor mismatch repair deficiency and increased mutational burden in blood and tissue of metastatic colorectal cancer patients treated with temozolomide

Author

Crisafulli, Giovanni, primary, Sartore-Bianchi, Andrea, additional, Lazzari, Luca, additional, Pietrantonio, Filippo, additional, Amatu, Alessio, additional, Macagno, Marco, additional, Barault, Ludovic, additional, Cassingena, Andrea, additional, Bartolini, Alice, additional, Luraghi, Paolo, additional, Mauri, Gianluca, additional, Battuello, Paolo, additional, Personemi, Nicola, additional, Pessei, Valeria, additional, Vitiello, Pietro Paolo, additional, Tosi, Federica, additional, Idotta, Laura, additional, Valtorta, Emanuele, additional, Bonoldi, Emanuela, additional, Germano, Giovanni, additional, Nicolantonio, Federica Di, additional, Marsoni, Silvia, additional, Siena, Salvatore, additional, and Bardelli, Alberto, additional

Published
2022
Full Text
View/download PDF

39. Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients

Author

Crisafulli, Giovanni, primary, Sartore-Bianchi, Andrea, additional, Lazzari, Luca, additional, Pietrantonio, Filippo, additional, Amatu, Alessio, additional, Macagno, Marco, additional, Barault, Ludovic, additional, Cassingena, Andrea, additional, Bartolini, Alice, additional, Luraghi, Paolo, additional, Mauri, Gianluca, additional, Battuello, Paolo, additional, Personeni, Nicola, additional, Zampino, Maria Giulia, additional, Pessei, Valeria, additional, Vitiello, Pietro Paolo, additional, Tosi, Federica, additional, Idotta, Laura, additional, Morano, Federica, additional, Valtorta, Emanuele, additional, Bonoldi, Emanuela, additional, Germano, Giovanni, additional, Di Nicolantonio, Federica, additional, Marsoni, Silvia, additional, Siena, Salvatore, additional, and Bardelli, Alberto, additional

Published
2022
Full Text
View/download PDF

40. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

Author

Sartore-Bianchi, Andrea, Ardini, Elena, Bosotti, Roberta, Amatu, Alessio, Valtorta, Emanuele, Somaschini, Alessio, Raddrizzani, Laura, Palmeri, Laura, Banfi, Patrizia, Bonazzina, Erica, Misale, Sandra, Marrapese, Giovanna, Leone, Antonella, Alzani, Rachele, Luo, David, Hornby, Zachary, Lim, Jonathan, Veronese, Silvio, Vanzulli, Angelo, Bardelli, Alberto, Martignoni, Marcella, Davite, Cristina, Galvani, Arturo, Isacchi, Antonella, and Siena, Salvatore

Published
2016
Full Text
View/download PDF

42. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Author

Siravegna, Giulia, Mussolin, Benedetta, Buscarino, Michela, Corti, Giorgio, Cassingena, Andrea, Crisafulli, Giovanni, Ponzetti, Agostino, Cremolini, Chiara, Amatu, Alessio, Lauricella, Calogero, Lamba, Simona, Hobor, Sebastijan, Avallone, Antonio, Valtorta, Emanuele, Rospo, Giuseppe, Medico, Enzo, Motta, Valentina, Antoniotti, Carlotta, Tatangelo, Fabiana, Bellosillo, Beatriz, Veronese, Silvio, Budillon, Alfredo, Montagut, Clara, Racca, Patrizia, Marsoni, Silvia, Falcone, Alfredo, Corcoran, Ryan B., Nicolantonio, Federica Di, Loupakis, Fotios, Siena, Salvatore, Sartore-Bianchi, Andrea, and Bardelli, Alberto

Subjects
Colorectal cancer -- Development and progression -- Genetic aspects -- Care and treatment -- Research, Biological sciences, Health
Abstract

Colorectal cancers (CRCs) evolve by a reiterative process of genetic diversification and clonal evolution. The molecular profile of CRC is routinely assessed in surgical or bioptic samples (1). Genotyping of CRC tissue has inherent limitations; a tissue sample represents a single snapshot in time, and it is subjected to spatial selection bias owing to tumor heterogeneity. Repeated tissue samples are difficult to obtain and cannot be used for dynamic monitoring of disease progression and response to therapy. We exploited circulating tumor DNA (ctDNA) to genotype colorectal tumors and track clonal evolution during treatment with the epidermal growth factor receptor (EGFR)-specific antibodies cetuximab or panitumumab. We identified alterations in ctDNA of patients with primary or acquired resistance to EGFR blockade in the following genes: KRAS, NRAS, MET, ERBB2, FLT3, EGFR and MAP2K1. Mutated KRAS clones, which emerge in blood during EGFR blockade, decline upon withdrawal of EGFR-specific antibodies, indicating that clonal evolution continues beyond clinical progression. Pharmacogenomic analysis of CRC cells that had acquired resistance to cetuximab reveals that upon antibody withdrawal KRAS clones decay, whereas the population regains drug sensitivity. ctDNA profiles of individuals who benefit from multiple challenges with anti-EGFR antibodies exhibit pulsatile levels of mutant KRAS. These results indicate that the CRC genome adapts dynamically to intermittent drug schedules and provide a molecular explanation for the efficacy of rechallenge therapies based on EGFR blockade., An improved understanding of the underlying molecular pathology of CRC has enabled tailored treatment regimens and helped optimize outcomes. CRC tissue is currently used to define the molecular status of [...]

Published
2015

45. Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment

Author

Amatu, Alessio, primary, Pani, Arianna, additional, Patelli, Giorgio, additional, Gagliardi, Oscar M., additional, Loparco, Marina, additional, Piscazzi, Daniele, additional, Cassingena, Andrea, additional, Tosi, Federica, additional, Ghezzi, Silvia, additional, Campisi, Daniela, additional, Grifantini, Renata, additional, Abrignani, Sergio, additional, Siena, Salvatore, additional, Scaglione, Francesco, additional, and Sartore-Bianchi, Andrea, additional

Published
2022
Full Text
View/download PDF

47. Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study

Author

Amatu, Alessio, primary, Mauri, Gianluca, additional, Tosi, Federica, additional, Bencardino, Katia, additional, Bonazzina, Erica, additional, Gori, Viviana, additional, Ruggieri, Lorenzo, additional, Arena, Sabrina, additional, Bardelli, Alberto, additional, Marsoni, Silvia, additional, Siena, Salvatore, additional, and Sartore-Bianchi, Andrea, additional

Published
2022
Full Text
View/download PDF

48. Efficacy of retreatment with oxaliplatin-based regimens in metastatic colorectal cancer patients: The RETROX-CRC retrospective study.

Author

Mauri, Gianluca, primary, Amatu, Alessio, additional, Tosi, Federica, additional, Bencardino, Katia, additional, Bonazzina, Erica, additional, Gori, Viviana, additional, Ruggieri, Lorenzo, additional, Arena, Sabrina, additional, Bardelli, Alberto, additional, Marsoni, Silvia, additional, Siena, Salvatore, additional, and Sartore-Bianchi, Andrea, additional

Published
2022
Full Text
View/download PDF

49. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)

Author

Leone, Francesco, Marino, Donatella, Cereda, Stefano, Filippi, Roberto, Belli, Carmen, Spadi, Rosella, Nasti, Guglielmo, Montano, Massimo, Amatu, Alessio, Aprile, Giuseppe, Cagnazzo, Celeste, Fasola, Gianpiero, Siena, Salvatore, Ciuffreda, Libero, Reni, Michele, and Aglietta, Massimo

Published
2016
Full Text
View/download PDF

50. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Author

Desai, Jayesh, Alonso, Guzman, Kim, Se Hyun, Cervantes, Andres, Karasic, Thomas, Medina, Laura, Shacham-Shmueli, Einat, Cosman, Rasha, Falcon, Alejandro, Gort, Eelke, Guren, Tormod, Massarelli, Erminia, Miller, Wilson H., Paz-Ares, Luis, Prenen, Hans, Amatu, Alessio, Cremolini, Chiara, Kim, Tae Won, Moreno, Victor, Ou, Sai-Hong I., Passardi, Alessandro, Sacher, Adrian, Santoro, Armando, Stec, Rafal, Ulahannan, Susanna, Arbour, Kathryn, Lorusso, Patricia, Luo, Jia, Patel, Manish R., Choi, Yoonha, Shi, Zhen, Mandlekar, Sandhya, Lin, Mark T., Royer-Joo, Stephanie, Chang, Julie, Jun, Tomi, Dharia, Neekesh V., Schutzman, Jennifer L., and Han, Sae-Won

Abstract

KRAS G12Cmutation is prevalent in ~4% of colorectal cancer (CRC) and is associated with poor prognosis. Divarasib, a KRAS G12C inhibitor, has shown modest activity as a single agent in KRAS G12C-positive CRC at 400 mg. Epidermal growth factor receptor has been recognized as a major upstream activator of RAS–MAPK signaling, a proposed key mechanism of resistance to KRAS G12C inhibition in CRC. Here, we report on divarasib plus cetuximab (epidermal growth factor receptor inhibitor) in patients with KRAS G12C-positive CRC (n= 29) from arm C of an ongoing phase 1b trial. The primary objective was to evaluate safety. Secondary objectives included preliminary antitumor activity. The safety profile of this combination was consistent with those of single-agent divarasib and cetuximab. Treatment-related adverse events led to divarasib dose reductions in four patients (13.8%); there were no treatment withdrawals. The objective response rate was 62.5% (95% confidence interval: 40.6%, 81.2%) in KRAS G12C inhibitor-naive patients (n= 24). The median duration of response was 6.9 months. The median progression-free survival was 8.1 months (95% confidence interval: 5.5, 12.3). As an exploratory objective, we observed a decline in KRAS G12Cvariant allele frequency associated with response and identified acquired genomic alterations at disease progression that may be associated with resistance. The manageable safety profile and encouraging antitumor activity of divarasib plus cetuximab support the further investigation of this combination in KRAS G12C-positive CRC.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results